Cyclerion Therapeutics, INC Schedule 13G passive stakes

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 7.0% of Cyclerion Therapeutics, Inc. common stock as of June 30, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 317,511 shares, representing 7.33% of Cyclerion Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 15.0% of Cyclerion Therapeutics Inc.'s common stock as of April 30, 2026.

J. Wood Capital Advisors LLC and Jason Wood have disclosed a 5.4% beneficial ownership stake in Cyclerion Therapeutics, Inc., holding 181,818 shares of common stock.

Tyndall Capital Partners, L.P. reports a 4.8% passive ownership stake in Cyclerion Therapeutics, Inc. as of June 30, 2025.

Tyndall Capital Partners, L.P. has filed an amended Schedule 13G, reporting a 5.1% beneficial ownership stake in Cyclerion Therapeutics, Inc. as of March 31, 2025.

MFN Partners and its affiliated entities have filed an Amendment No. 2 to Schedule 13G, indicating a complete divestment of their beneficial ownership in Cyclerion Therapeutics, Inc., now holding 0% of the common stock.

American Endowment Foundation has filed an Amendment No. 2 to Schedule 13G, disclosing a 4.91% beneficial ownership stake in Cyclerion Therapeutics Inc. as of December 31, 2024.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a passive beneficial ownership of 0.2% in Cyclerion Therapeutics Inc. as of December 31, 2024.